Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ADH300004 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| ADH300004 | DRUG | - |
Inclusion Criteria: * Signed written informed consent * \> or = 19 years of age * Patients with histologically confirmed: * primary or metastatic (known or suspected) colorectal carcinoma requiring planned surgical resection with hepatic biopsy and systemic chemotherapy , or * primary or metas...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
ADH300004 is an investigational small molecule developed by Fennec Pharmaceuticals Inc. (ticker FENC) for neoplasms in the oncology therapeutic area. It has been studied in a Phase 1 clinical trial in patients with surgically resected primary or metastatic colorectal cancer who underwent liver biopsy or planned hepatic resection.
ADH300004 has been studied for neoplasms, specifically in patients with surgically resected primary or metastatic colorectal cancer and liver biopsy, or planned hepatic resection. It is an investigational agent in the oncology therapeutic area and is not an approved treatment for any indication.
ADH300004 is developed by Fennec Pharmaceuticals Inc., which trades under the ticker FENC. The company is the sponsor of the clinical program evaluating this small molecule in oncology.
ADH300004 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are currently listed. Because it remains investigational, ADH300004 is not FDA approved for any indication.
ADH300004 has been evaluated in one Phase 1 trial, NCT00264446, titled A Study of ADH300004 in Surgically Resected Primary or Metastatic Colorectal Cancer and Liver Biopsy, or Planned Hepatic Resection. The trial was completed in the United States and enrolled patients aged 19 years and older.